A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

R. Galot,C. Le Tourneau, L. F. L. Licitra,C. Even,A. Daste,S. Henry, C. Borel, C. Abdeddaim, E. Seront, J. B. Prevost, A. Rutten, E. B. Saada, F. Rolland, L. Livi, P. M. C. Specenier, J. Leys, C. Olungu,C. Fortpied Lefevre, A. Joaquim,J-P. Machiels

ANNALS OF ONCOLOGY(2023)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要